Source: Virtual Congress 2020 – Clinical evaluation, biomarkers and risk assessment of pulmonary hypertension
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
P. Rosenstock (Graz, Austria), K. Zeder (Graz, Austria), A. Avian (Graz, Austria), G. Bachmaier (Graz, Austria), P. Douschan (Graz, Austria), V. Foris (Graz, Austria), T. Sassmann (Graz, Austria), H. Olschewski (Graz, Austria), G. Kovacs (Graz, Austria). Impact of the new definition of precapillary pulmonary hypertension on patient disposition. 1529

Member's Comments

No comment yet.

Related content which might interest you: The new definition of pulmonary hypertension Source: Eur Respir J 2009; 34: 790-791 Year: 2009 Identification of treatment goals in paediatric pulmonary arterial hypertension Source: Eur Respir J 2014; 44: 1616-1626 Year: 2014 Evaluation of criteria for exercise-induced pulmonary hypertension in patients with resting pulmonary hypertension Source: Eur Respir J, 50 (3) 1700784; 10.1183/13993003.00784-2017 Year: 2017 The importance of patient perspectives in pulmonary hypertension Source: Eur Respir J, 53 (1) 1801919; 10.1183/13993003.01919-2018 Year: 2019 Pulmonary vascular resistance and compliance relationship in pulmonary hypertension Source: Eur Respir J 2015; 46: 1178-1189 Year: 2015 Challenging the concept of adding more drugs in pulmonary arterial hypertension Source: Eur Respir J, 50 (3) 1701527; 10.1183/13993003.01527-2017 Year: 2017 Update on current treatment options of pulmonary hypertension Source: Annual Congress 2006 - Pulmonary hypertension at the crossroads of science and clinical medicine Year: 2006 Population pharmacokinetics of imatinib in patients with pulmonary arterial hypertension Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment Year: 2013 Risk assessment in pulmonary arterial hypertension Source: Eur Respir J, 51 (3) 1702606; 10.1183/13993003.02606-2017 Year: 2018 Risk assessment in pulmonary arterial hypertension Source: Eur Respir Rev 2016; 25: 390-398 Year: 2016 Risk assessment in pulmonary arterial hypertension Source: Eur Respir J, 51 (3) 1800279; 10.1183/13993003.00279-2018 Year: 2018 The French registry of pulmonary arterial hypertension in children: characteristics at diagnosis Source: Annual Congress 2007 - Clinical aspects of pulmonary arterial hypertension Year: 2007 Impact of pulmonary arterial hypertension (PAH) on the lives of patients and carers Source: Annual Congress 2013 –Pulmonary circulation: clinical pulmonary hypertension I Year: 2013 Adherence to disease-specific drug treatment among patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension Source: ERJ Open Res, 6 (4) 00299-2020; 10.1183/23120541.00299-2020 Year: 2020 Long-term safety of a new formulation of epoprostenol in pulmonary arterial hypertension Source: Annual Congress 2013 –Pulmonary circulation: clinical diagnosis, imaging, biomarkers and treatment Year: 2013 Current practice for determining pulmonary capillary wedge pressure predisposes to serious errors in the classification of patients with pulmonary hypertension Source: Annual Congress 2011 - Clinical characteristics of patients with pulmonary hypertension Year: 2011 Impact on survival of pulmonary function abnormalities in pulmonary arterial hypertension Source: Annual Congress 2009 - Pulmonary hypertension Year: 2009 Treatment options for paediatric pulmonary arterial hypertension Source: Eur Respir Rev 2010 19: 321-330 Year: 2010 Effect of riociguat on pulmonary arterial compliance in patients with pulmonary arterial hypertension (PAH) in the RESPITE study Source: International Congress 2017 – New insights into pulmonary hypertension from recent trials Year: 2017